Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure
about
Insulin-like growth factor (IGF-I) induces myotube hypertrophy associated with an increase in anaerobic glycolysis in a clonal skeletal-muscle cell modelDifferential regulation of the phosphatidylinositol 3-kinase/Akt and p70 S6 kinase pathways by the alpha(1A)-adrenergic receptor in rat-1 fibroblastsProtein kinase cascades in the regulation of cardiac hypertrophyHarnessing Hippo in the heart: Hippo/Yap signaling and applications to heart regeneration and rejuvenationParacrine mechanisms in adult stem cell signaling and therapyPOTENTIAL NON-GROWTH USES OF rhIGF-IGrowth hormone and the heart.Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction.The GH/IGF-1 Axis and Heart Failure.Association of leukocyte telomere length with echocardiographic left ventricular mass: the Framingham heart studyCytokines and their receptors in cardiovascular diseases--role of gp130 signalling pathway in cardiac myocyte growth and maintenance.Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy.Advances in the treatment of congestive heart failure: new approaches for an old disease.Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesisAdministration of a Synthetic Peptide Derived from the E-domain Region of Mechano-Growth Factor Delays Decompensation Following Myocardial Infarction.Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease.Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarctionDeletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy.Prospective study of insulin-like growth factor-I, insulin-like growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease.Insulin-like growth factor I and II preserve myocardial structure in postinfarct swine.Cardiac proteasome activity in muscle ring finger-1 null mice at rest and following synthetic glucocorticoid treatment.Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis.The insulin-like growth factor system: towards clinical applications.Improved function of the failing rat heart by regulated expression of insulin-like growth factor I via intramuscular gene transfer.Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner.Locally expressed IGF1 propeptide improves mouse heart function in induced dilated cardiomyopathy by blocking myocardial fibrosis and SRF-dependent CTGF induction.Ras-dependent pathways induce obstructive hypertrophy in echo-selected transgenic mice.Growth hormone therapy in heart failure: a novel therapy worthy of further consideration?A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel.Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysisChronic treatment with insulin-like growth factor I enhances myocyte contraction by upregulation of Akt-SERCA2a signaling pathway.Emerging Concepts in Paracrine Mechanisms in Regenerative Cardiovascular Medicine and Biology.The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarctionIGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro.Akt regulates L-type Ca2+ channel activity by modulating Cavalpha1 protein stability.IGF-1 deficiency resists cardiac hypertrophy and myocardial contractile dysfunction: role of microRNA-1 and microRNA-133a.1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes.Elevated blood pressure and enhanced myocardial contractility in mice with severe IGF-1 deficiency.Thyroid hormone improves function and Ca2+ handling in pressure overload hypertrophy. Association with increased sarcoplasmic reticulum Ca2+-ATPase and alpha-myosin heavy chain in rat hearts.The role of insulin-like growth factor during a postischemic period - new insights into pathophysiologic pathways in cardiac tissue.
P2860
Q22009148-3338FAE7-50A8-4427-BCF0-9A9347C84E70Q22253167-5DC7382A-E04E-47EC-B8F5-22F94315775AQ24518494-BE68BACE-41E8-4D24-8862-82434362E35BQ26995264-CC287E5E-A642-47D5-8B38-FB9065D5690DQ29620571-1724A059-E9E4-46B6-8BE0-DC2CEE970A6FQ30492205-09F7273A-3297-4CB9-BA10-89B913DE8581Q32026861-1C640DFE-6A3B-4000-8A82-A4FC0495BA4DQ33585711-4F57B839-03E6-4716-B9D9-0FAAC11EAA4FQ33654009-439121DB-5DA2-46FD-BB3F-A8710381049CQ33802557-3C625A32-29C4-4392-AD44-6154B8C13800Q33863961-9B6B39AB-DDE7-4FCE-A0B4-4AAB6FDC6A40Q33869828-DF56F737-D20E-42B2-8C1E-6AA62AC4353AQ33977639-CDBCF60B-DB80-4FD1-91DF-19B4AEFEC27CQ34470451-380689A4-6FF0-4E98-848E-F2EF06E8D892Q34979969-3E9EB3B8-9CC6-4F46-9F3A-1D3E9D6F720FQ35070251-16FCDAF3-4ECD-4863-AE79-092D1CF37957Q35083679-02D324E5-DB25-45D8-824B-45AE0B76027FQ35126646-82EA7116-FC63-43EF-98BB-A051DA779B1AQ35193839-77AD3C38-0958-41A6-ADDE-7D108381640BQ35382248-E74D72B2-EFAD-4634-A340-E6034AFF4328Q35543645-D814836D-CB7D-493B-BFC2-9CEF6F2C0838Q35745296-9A98ACC7-7A48-4D72-8E56-EF0C4B5E7A51Q35819252-A5535E24-F879-48D0-B261-009F7BC88AF3Q35823919-BBF04F2E-3C50-41B4-9155-E756D46AFD1CQ35963179-EC55DCB5-50C4-4112-AEC6-987CBF00053EQ36051055-03D1D8F9-2C24-4B60-BCBC-D9E33A8D3D3DQ36146023-0714A9A6-F6B9-44A5-9652-16E5FA0329EDQ36210914-0B1C0B03-6755-4523-9F3F-54FB64C7F7F3Q36323554-0C9804E6-CB36-45B2-9EE8-C7F5043B45D8Q36497030-A068E441-75C9-428C-92DD-0B12BE6D1016Q36807914-874255BC-8199-4652-AD23-D55C4BF49345Q36920724-D4334B62-159A-48D5-8B0D-178F91F2A308Q37039373-BB43EA5C-3C2D-4737-8CD4-0B014DEDA5C0Q37131600-3DED29B0-FD11-4817-9119-E6D67F6F786DQ37234352-7B087127-4E05-4247-88FD-0A326F865E43Q37295216-62B7F409-D465-46A0-A805-0F9BB5F3DDEEQ37353500-2E0FD131-BC79-405F-9517-BF450102817FQ37361963-12A17FF4-9D27-44CB-A071-4B482156987FQ37372872-6390D804-A628-4251-B9F7-0D7D3693A420Q37608512-88BBD2EE-8C97-4DDC-BBF0-08A87D76EE82
P2860
Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure
description
1995 nî lūn-bûn
@nan
1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Insulin-like growth factor-1 e ...... f experimental cardiac failure
@ast
Insulin-like growth factor-1 e ...... f experimental cardiac failure
@en
Insulin-like growth factor-1 e ...... f experimental cardiac failure
@nl
type
label
Insulin-like growth factor-1 e ...... f experimental cardiac failure
@ast
Insulin-like growth factor-1 e ...... f experimental cardiac failure
@en
Insulin-like growth factor-1 e ...... f experimental cardiac failure
@nl
prefLabel
Insulin-like growth factor-1 e ...... f experimental cardiac failure
@ast
Insulin-like growth factor-1 e ...... f experimental cardiac failure
@en
Insulin-like growth factor-1 e ...... f experimental cardiac failure
@nl
P2093
P2860
P356
P1476
Insulin-like growth factor-1 e ...... f experimental cardiac failure
@en
P2093
P2860
P304
P356
10.1172/JCI117706
P407
P577
1995-02-01T00:00:00Z